Consistently, our findings suggest that MYC downregulation by miR-22 increases NK-activating ligands on the MM cell surface, such as MICA/B and ULBP 2/5/6, and a downregulation of NK-inhibiting ligands, such as CD47. This evidence concerns the gene MYC and Miyoshi myopathy.